Coenzyme A (CoA) is a primary and predominant acyl group carrier involved in a wide variety of important biochemical processes. The CoA biosynthetic pathway is composed of five enzymatic steps, of which Pantothenate kinase (PanK) is a key regulatory enzyme. The multiple isoforms of PanK are encoded by four different genes [1, 2] . In our previous studies of SNP markers by genotyping the case-controlled DNAs, we found that one SNP within the hPANK4 gene on chromosome 1 was associated with type 2 diabetes [3] [4] [5] . We subsequently showed that rat PanK4 (rPanK4) was up-regulated when rats were challenged by high concentration of glucose [6] . M2-type pyruvate kinase (Pkm2) was found, both in vitro and in vivo, to be associated with rPanK4 [7] . These data suggest that PanK4 may have a role in diabetes pathogenesis. The development of type 2 diabetes is due partly to the loss of the pancreatic β-cell mass, therefore the secreted amount of insulin is insufficient to maintain the glucose homoestasis [8] . In the present study, we evaluated the effect of rPanK4 on β-cell apoptosis. We aimed to determine the potential of rPanK4 gene in β-cell apoptosis induced by the cytotoxic agent streptozotocin (STZ).
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Coenzyme A (CoA) is a primary and predominant acyl group carrier involved in a wide variety of important biochemical processes. The CoA biosynthetic pathway is composed of five enzymatic steps, of which Pantothenate kinase (PanK) is a key regulatory enzyme. The multiple isoforms of PanK are encoded by four different genes [1, 2] . In our previous studies of SNP markers by genotyping the case-controlled DNAs, we found that one SNP within the hPANK4 gene on chromosome 1 was associated with type 2 diabetes [3] [4] [5] . We subsequently showed that rat PanK4 (rPanK4) was up-regulated when rats were challenged by high concentration of glucose [6] . M2-type pyruvate kinase (Pkm2) was found, both in vitro and in vivo, to be associated with rPanK4 [7] . These data suggest that PanK4 may have a role in diabetes pathogenesis. The development of type 2 diabetes is due partly to the loss of the pancreatic β-cell mass, therefore the secreted amount of insulin is insufficient to maintain the glucose homoestasis [8] . In the present study, we evaluated the effect of rPanK4 on β-cell apoptosis. We aimed to determine the potential of rPanK4 gene in β-cell apoptosis induced by the cytotoxic agent streptozotocin (STZ).
We generated a rat RINm5F cell line (insulin-secreting tumor cell line) overexpressing recombinant rPanK4 (rPanK4-RINm5F). Cells transfected with empty vector (empty-RINm5F) were used as the negative control (Figure 1A) . We examined the effects of rPanK4 on cellular proliferation by MTT assay. Data shows that there were little differences in rates of cellular proliferation comparing the control and rPanK4-RINm5F cells. Accordingly, we focused on the potential role of rPanK4 in apoptosis process. Here, we used FACS to investigate the role of rPanK4 in STZ-induced apoptosis. RINm5F cells were exposed to a series of concentrations of STZ at the different time points. The apoptosis rate of rPanK4-RINm5F cells was significantly reduced compared to control cells only when cells were exposed to 2.5 mg/ml of STZ for 24 h. When RINm5F and empty-RINm5F transfected cells were exposed to 2.5 mg/ml of STZ, the apoptosis rate increased from 6.1 ± 0.7% to 19.5 ± 0.9% and from 7.3 ± 0.4% to 20.3 ± 0.7% respectively. By contrast, the apoptosis rate of the rPanK4-RINm5F cells only slightly increased to 11.1 ± 1.2% (p<0.01) ( Figure 1B1 ). The rPanK4 protective effect was further evaluated by using TUNEL and DNA ladder assays. The apoptosis ( Figure 1B2 , B4, B5, B6) and DNA fragmentation ( Figure 1B3 ) were significantly decreased in rPanK4-overexpressing cells when exposed to 2.5 mg/ml of STZ for 24 h.
We further examined the effects of rPanK4 on apoptosisrelated genes by quantitative real-time PCR. Overexpression of rPanK4 significantly reduced the expression level of the pro-caspase-9 mRNA by more than 50%, but not other apoptosis-related genes, including Bcl-2, Bax, Bad, pro-caspase-3, and pro-caspase-8 genes ( Figure 1C) . At protein level, pro-caspase-9 was significantly decreased in rPanK4-RINm5F cells. However, the pro-caspase-3 expression levels were not significantly different between rPanK4-RINm5F and RINm5F cells ( Figure 1D1) .
We analyzed the caspase activation by colorimetric and western blot assays. Caspase-3 and caspase-9 activities Figure 1D2 , D3, D4). Taken together, it might imply that overexpression of rPanK4 partially inhibited the caspase-3 and caspase-9 activities in STZ-induced apoptosis in RINm5F cells. Moreover, the decrease in the caspase-3 activity was correlated with the decreased caspase-9 activity. To test whether the decrease of caspase-9 activity was due to the changes of cytochrome c, we compared the level of cytochrome c in cytosol in RINm5F and rPanK4-RINm5F cells by western blot. Figure 1D shows that the level of cytochrome c in rPanK4-RINm5F cells was similar to that in the control cells. The result of cytosol cytochrome c also suggested that overexpressing rPanK4 had little effect on the mitochondrial function.
In our previous studies, PanK4 was shown to be related to diabetes. Interestingly, PanK4 does not possess a kinase activity and thus does not change cell proliferation/apop- tosis via its activity in CoA metabolism [9] . Evidence with the Drosophila orthologue of PanK gene fumble (fbl) suggested a CoA-independent role in cell proliferation [10] . We showed that STZ-stimulated apoptosis was significantly blocked by an overexpression of rPanK4. In the present study, rPanK4 expression led to decreased pro-caspase-9 mRNA level. Accordingly, the expression of pro-caspase-9 protein also decreased. Consistently, rPanK4-overexpressing cells underwent significantly lower caspase-3 activation when treated with STZ.
In conclusion, our current study suggests that rPanK4 has an anti-apoptotic effect, via down-regulating caspase-9. Given this novel finding, future studies are needed to elucidate the biological functions and molecular mechanisms of PanK4 in type 2 diabetes.
